研究用フローサイトと理化学分析

世界のリサーチ分野のお客さまへ先端の検査装置のご案内です。

お問い合わせはこちら

sysmex

研究用フローサイトと理化学分析sysmex

CyFlow CD34 Pacific Blue

品番 AE506357
抗体名 Anti-Hu CD34 PAC BLUE,4H11[APG]
包装単位 100 tests
濃度 -
容量 0.4 ml
関連製品
(アイソタイプコントロール)
Mouse IgG1 Pacific Blue™ (AP887259)
反応性|交差吸着 Human レーザー Violet
抗原 CD34 最大蛍光波長 455 nm
クローン 4H11[APG] 最大励起波長 400 to 410 nm
ホスト Mouse 標識/Format Pacific Blue™
アイソタイプ IgG1 研究分野 Immunophenotyping
クローナリティ monoclonal 用途

Flow cytometry

Anti-Hu CD34 PAC BLUE,4H11[APG]

特異性

The mouse monoclonal antibody 4H11[APG] recognizes Class III epitope on CD34 antigen, a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody 4H11[APG] completely blocks binding of Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and 8G12 on KG1a cell line.

抗原情報

CD34 (Mucosialin) is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.

利用方法

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

保存方法

Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.

安定性情報

Do not use after expiration date stamped on vial label.

レファレンス

• Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003·Jan·1; 101(1):112‑8. <·PMID:·12589631·>
• Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. Neoplasma. 2007; 54(4):311‑20. <·PMID:·17822321·>
• Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three‑dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk‑L. Stem·Cells·Dev. 2005·Oct; 14(5):470‑7. <·PMID:·16305332·>
• Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem·Cells·Dev. 2006·Jun; 15(3):305‑13. <·PMID:·16846369·>
• Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL‑2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J·Leukoc·Biol. 2005·Sep; 78(3):725‑35. <·PMID:·16000396·>
• Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor‑mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti‑HPCA‑1. J·Hematother·Stem·Cell·Res. 2001·Dec; 10(6):863‑71. <·PMID:·11798512·>